Background Catheter ablation reduces ventricular tachycardia (VT) recurrence and implantable cardioverter defibrillator shocks in patients with VT and ischemic cardiomyopathy. The most effective catheter ablation technique is unknown. Objectives This study determined rates of VT recurrence in patients undergoing ablation limited to clinical VT along with mappable VTs ("clinical ablation") versus substrate-based ablation. Methods Subjects with ischemic cardiomyopathy and hemodynamically tolerated VT were randomized to clinical ablation (n = 60) versus substrate-based ablation that targeted all "abnormal" electrograms in the scar (n = 58). Primary endpoint was recurrence of VT. Secondary endpoints included periprocedural complications, 12-month mortality, and rehospitalizations. Results At 12-month follow-up, 9 (15.5%) and 29 (48.3%) patients had VT recurrence in substrate-based and clinical VT ablation groups, respectively (log-rank p < 0.001). More patients undergoing clinical VT ablation (58%) were on antiarrhythmic drugs after ablation versus substrate-based ablation (12%; p < 0.001). Seven (12%) patients with substrate ablation and 19 (32%) with clinical ablation required rehospitalization (p = 0.014). Overall 12-month mortality was 11.9%; 8.6% in substrate ablation and 15.0% in clinical ablation groups, respectively (log-rank p = 0.21). Combined incidence of rehospitalization and mortality was significantly lower with substrate ablation (p = 0.003). Periprocedural complications were similar in both groups (p = 0.61). Conclusions An extensive substrate-based ablation approach is superior to ablation targeting only clinical and stable VTs in patients with ischemic cardiomyopathy presenting with tolerated VT. (Ablation of Clinical Ventricular Tachycardia Versus Addition of Substrate Ablation on the Long Term Success Rate of VT Ablation (VISTA); NCT01045668)

Di Biase, L., Burkhardt, J. D., Lakkireddy, D., Carbucicchio, C., Mohanty, S., Mohanty, P., Trivedi, C., Santangeli, P., Bai, R., Forleo, G., Horton, R., Bailey, S., Sanchez, J., Al-ahmad, A., Hranitzky, P., Gallinghouse, G. J., Pelargonio, G., Hongo, R. H., Beheiry, S., Hao, S. C., Reddy, M., Rossillo, A., Themistoclakis, S., Dello Russo, A., Casella, M., Tondo, C., Natale, A., Ablation of Stable VTs Versus Substrate Ablation in Ischemic Cardiomyopathy the VISTA Randomized Multicenter Trial, <<JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY>>, 2015; 66 (25): 2872-2882. [doi:10.1016/j.jacc.2015.10.026] [http://hdl.handle.net/10807/172373]

Ablation of Stable VTs Versus Substrate Ablation in Ischemic Cardiomyopathy the VISTA Randomized Multicenter Trial

Pelargonio, G.;Dello Russo, A.;Casella, M.;
2015

Abstract

Background Catheter ablation reduces ventricular tachycardia (VT) recurrence and implantable cardioverter defibrillator shocks in patients with VT and ischemic cardiomyopathy. The most effective catheter ablation technique is unknown. Objectives This study determined rates of VT recurrence in patients undergoing ablation limited to clinical VT along with mappable VTs ("clinical ablation") versus substrate-based ablation. Methods Subjects with ischemic cardiomyopathy and hemodynamically tolerated VT were randomized to clinical ablation (n = 60) versus substrate-based ablation that targeted all "abnormal" electrograms in the scar (n = 58). Primary endpoint was recurrence of VT. Secondary endpoints included periprocedural complications, 12-month mortality, and rehospitalizations. Results At 12-month follow-up, 9 (15.5%) and 29 (48.3%) patients had VT recurrence in substrate-based and clinical VT ablation groups, respectively (log-rank p < 0.001). More patients undergoing clinical VT ablation (58%) were on antiarrhythmic drugs after ablation versus substrate-based ablation (12%; p < 0.001). Seven (12%) patients with substrate ablation and 19 (32%) with clinical ablation required rehospitalization (p = 0.014). Overall 12-month mortality was 11.9%; 8.6% in substrate ablation and 15.0% in clinical ablation groups, respectively (log-rank p = 0.21). Combined incidence of rehospitalization and mortality was significantly lower with substrate ablation (p = 0.003). Periprocedural complications were similar in both groups (p = 0.61). Conclusions An extensive substrate-based ablation approach is superior to ablation targeting only clinical and stable VTs in patients with ischemic cardiomyopathy presenting with tolerated VT. (Ablation of Clinical Ventricular Tachycardia Versus Addition of Substrate Ablation on the Long Term Success Rate of VT Ablation (VISTA); NCT01045668)
Inglese
Di Biase, L., Burkhardt, J. D., Lakkireddy, D., Carbucicchio, C., Mohanty, S., Mohanty, P., Trivedi, C., Santangeli, P., Bai, R., Forleo, G., Horton, R., Bailey, S., Sanchez, J., Al-ahmad, A., Hranitzky, P., Gallinghouse, G. J., Pelargonio, G., Hongo, R. H., Beheiry, S., Hao, S. C., Reddy, M., Rossillo, A., Themistoclakis, S., Dello Russo, A., Casella, M., Tondo, C., Natale, A., Ablation of Stable VTs Versus Substrate Ablation in Ischemic Cardiomyopathy the VISTA Randomized Multicenter Trial, <<JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY>>, 2015; 66 (25): 2872-2882. [doi:10.1016/j.jacc.2015.10.026] [http://hdl.handle.net/10807/172373]
File in questo prodotto:
File Dimensione Formato  
172373OA.pdf

non disponibili

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Non specificato
Dimensione 1.92 MB
Formato Unknown
1.92 MB Unknown   Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/172373
Citazioni
  • ???jsp.display-item.citation.pmc??? 54
  • Scopus 216
  • ???jsp.display-item.citation.isi??? 178
social impact